CG Oncology (CGON) Cash from Operations (2023 - 2026)
CG Oncology (CGON) posted Cash from Operations of 56900000.0 for Q1 2026, down 57.18% on a QoQ basis from 36200000.0 in Q4 2025, and down 94.35% year-over-year from 1007171281.74 in Q1 2025.
CG Oncology (CGON) Cash from Operations (2023 - 2026) Analysis & Trends
CG Oncology's Cash from Operations history runs 4 years deep, the most recent figure standing at 56900000.0 for Q1 2026.
- Quarterly Cash from Operations fell 94.35% year-over-year to 56900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 159923000.0 (down 95.08% YoY) and the FY2025 annual result came in at 132300000.0, down 68.08% from the prior year.
- Cash from Operations was 56900000.0 for Q1 2026 at CG Oncology, down from 36200000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 7986000.0 in Q1 2023 and bottomed at 56900000.0 in Q1 2026.
- A 4-year average of 24122461.54 and a median of 20662000.0 in 2024 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations tumbled 225.72% — and 2025, when it dropped 12.55%.
- CG Oncology's Cash from Operations stood at 14645000.0 in 2023, then slumped by 41.09% to 20662000.0 in 2024, then slumped by 75.2% to 36200000.0 in 2025, then tumbled by 57.18% to 56900000.0 in 2026.
- Business Quant data shows CGON's Cash from Operations at 56900000.0 in Q1 2026, 36200000.0 in Q4 2025, and 38864000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 201.34 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.53 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -354.17 Mn |
| 10 | CG Oncology | 6.01 Bn | 6.01 Bn | -1.88 Mn | -56.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.90 Mn |
| Mar 31, 2026 | -56.90 Mn |
| Dec 31, 2025 | -36.20 Mn |
| Dec 31, 2025 | -36.20 Mn |
| Sep 30, 2025 | -38.86 Mn |
| Sep 30, 2025 | -38.86 Mn |
| Jun 30, 2025 | -27.96 Mn |
| Jun 30, 2025 | -27.96 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Mar 31, 2025 | -29.28 Mn |
| Dec 31, 2024 | -20.66 Mn |
| Dec 31, 2024 | -20.66 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Sep 30, 2024 | -15.92 Mn |
| Jun 30, 2024 | -16.12 Mn |
| Jun 30, 2024 | -16.12 Mn |
| Mar 31, 2024 | -26.01 Mn |
| Mar 31, 2024 | -26.01 Mn |
| Dec 31, 2023 | -14.65 Mn |
| Dec 31, 2023 | -14.65 Mn |